Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
      Description

      This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

      Conditions
      Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene Fusion/RearrangementFGFR2 Gene AmplificationFGFR2 Gene Short VariantsFGFR3 Gene Fusion/RearrangementFGFR3 Gene AmplificationFGFR3 Gene Short VariantsFGFR2 Genetic AlterationsFGFR3 Genetic AlterationsAdvanced Solid Tumors
      Talk to us
      COMPLETED
      Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
      Description

      This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR genetic aberrations, including iCCA with FGFR2 gene fusion (Part 2; Expanded Cohort, signal finding).

      Conditions
      Solid Tumor
      Talk to us
      TERMINATED
      A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
      Description

      This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.

      Conditions
      Advanced CholangiocarcinomaFGFR2 Gene Mutation
      Talk to us